ANG-3777 Treatment of COVID-19 Acute Lung Injury: Phase II Clinical Trials Launched

Biopharmaceutical company Angion announced that it has launched a randomized placebo-controlled Phase II clinical trial in Brazil to study the effectiveness of THE ANG-3777 joint standard therapy treatmentCOVID-19pneumonia-related acute lung injurythis is a multicenter, forward-looking, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of ANG-3777 in hospitalized patients with confirmed COVID-19 pneumoniaThe primary endpoint of the trial was the proportion of surviving patients who did not need mechanical ventilation and no kidney replacement therapy on day 28Angion expects to recruit about 100 patientsIf the Phase II trial is successful, Angion plans to file a research application for a new drug (IND) in the United Statesacute lung injury is a variety of direct and indirect injury factors caused by alveolar epithelial cells and capillariesvascularendothelial cell damage, resulting in diffuse interpulmonary matter and alcosafluidous edema, resulting in acute hypoxic respiratory dysfunctionThe pathophysiological characteristics were characterized by reduced lung volume, reduced lung compliance and disorder of ventilation/blood flow ratio